NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma

Stephen R. Mattarollo, Alison C. West, Kim Steegh, Helene Duret, Christophe Paget, Ben Martin, Geoffrey M. Matthews, Jake Shortt, Marta Chesi, Peter Leif Bergsagel, Michael Bots, Johannes Zuber, Scott W. Lowe, Ricky W. Johnstone, Mark J. Smyth

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Immunomodulators are effective in controlling hematologic malignancy by initiating or reactivating host antitumor immunity to otherwise poorly immunogenic and immune suppressive cancers. We aimed to boost antitumor immunity in B-cell lymphoma by developing a tumor cell vaccine incorporating (α-galactosylceramide (α-GalCer) that targets the immune adjuvant properties of NKT cells. In the Eμ-myc transgenic mouse model, single therapeutic vaccination of irradiated, (α-GalCer-loaded autologous tumor cells was sufficient to significantly inhibit growth of established tumors and prolong survival. Vaccine-induced antilymphoma immunity required NKT cells, NK cells, and CD8 T cells, and early IL-12-dependent production of IFN-γ. CD4 T cells, gamma/delta T cells, and IL-18 were not critical. Vaccine treatment induced a large systemic spike of IFN-(γ and transient peripheral expansion of both NKT cells and NK cells, the major sources of IFN-γ. Furthermore, this vaccine approach was assessed in several other hematopoietic tumor models and was also therapeutically effective against AMLETO9a acute myeloid leukemia. Replacing (α-GalCer with β-mannosylceramide resulted in prolonged protection against Eμ-myc lymphoma. Overall, our results demonstrate a potent immune adjuvant effect of NKT cell ligands in therapeutic anticancer vaccination against oncogenedriven lymphomas, and this work supports clinical investigation of NKT cell-based immunotherapy in patients with hematologic malignancies.

Original languageEnglish (US)
Pages (from-to)3019-3029
Number of pages11
JournalBlood
Volume120
Issue number15
DOIs
StatePublished - Oct 11 2012

Fingerprint

Cancer Vaccines
Natural Killer T-Cells
myc Genes
B-Cell Lymphoma
T-cells
Tumors
Vaccines
Cells
Immunity
Hematologic Neoplasms
T-Lymphocytes
Natural Killer Cells
Galactosylceramides
Lymphoma
Neoplasms
Vaccination
Interleukin-18
Immunologic Factors
Therapeutics
Interleukin-12

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Mattarollo, S. R., West, A. C., Steegh, K., Duret, H., Paget, C., Martin, B., ... Smyth, M. J. (2012). NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma. Blood, 120(15), 3019-3029. https://doi.org/10.1182/blood-2012-04-426643

NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma. / Mattarollo, Stephen R.; West, Alison C.; Steegh, Kim; Duret, Helene; Paget, Christophe; Martin, Ben; Matthews, Geoffrey M.; Shortt, Jake; Chesi, Marta; Bergsagel, Peter Leif; Bots, Michael; Zuber, Johannes; Lowe, Scott W.; Johnstone, Ricky W.; Smyth, Mark J.

In: Blood, Vol. 120, No. 15, 11.10.2012, p. 3019-3029.

Research output: Contribution to journalArticle

Mattarollo, SR, West, AC, Steegh, K, Duret, H, Paget, C, Martin, B, Matthews, GM, Shortt, J, Chesi, M, Bergsagel, PL, Bots, M, Zuber, J, Lowe, SW, Johnstone, RW & Smyth, MJ 2012, 'NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma', Blood, vol. 120, no. 15, pp. 3019-3029. https://doi.org/10.1182/blood-2012-04-426643
Mattarollo SR, West AC, Steegh K, Duret H, Paget C, Martin B et al. NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma. Blood. 2012 Oct 11;120(15):3019-3029. https://doi.org/10.1182/blood-2012-04-426643
Mattarollo, Stephen R. ; West, Alison C. ; Steegh, Kim ; Duret, Helene ; Paget, Christophe ; Martin, Ben ; Matthews, Geoffrey M. ; Shortt, Jake ; Chesi, Marta ; Bergsagel, Peter Leif ; Bots, Michael ; Zuber, Johannes ; Lowe, Scott W. ; Johnstone, Ricky W. ; Smyth, Mark J. / NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma. In: Blood. 2012 ; Vol. 120, No. 15. pp. 3019-3029.
@article{9262793a087844db988d895482e6236a,
title = "NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma",
abstract = "Immunomodulators are effective in controlling hematologic malignancy by initiating or reactivating host antitumor immunity to otherwise poorly immunogenic and immune suppressive cancers. We aimed to boost antitumor immunity in B-cell lymphoma by developing a tumor cell vaccine incorporating (α-galactosylceramide (α-GalCer) that targets the immune adjuvant properties of NKT cells. In the Eμ-myc transgenic mouse model, single therapeutic vaccination of irradiated, (α-GalCer-loaded autologous tumor cells was sufficient to significantly inhibit growth of established tumors and prolong survival. Vaccine-induced antilymphoma immunity required NKT cells, NK cells, and CD8 T cells, and early IL-12-dependent production of IFN-γ. CD4 T cells, gamma/delta T cells, and IL-18 were not critical. Vaccine treatment induced a large systemic spike of IFN-(γ and transient peripheral expansion of both NKT cells and NK cells, the major sources of IFN-γ. Furthermore, this vaccine approach was assessed in several other hematopoietic tumor models and was also therapeutically effective against AMLETO9a acute myeloid leukemia. Replacing (α-GalCer with β-mannosylceramide resulted in prolonged protection against Eμ-myc lymphoma. Overall, our results demonstrate a potent immune adjuvant effect of NKT cell ligands in therapeutic anticancer vaccination against oncogenedriven lymphomas, and this work supports clinical investigation of NKT cell-based immunotherapy in patients with hematologic malignancies.",
author = "Mattarollo, {Stephen R.} and West, {Alison C.} and Kim Steegh and Helene Duret and Christophe Paget and Ben Martin and Matthews, {Geoffrey M.} and Jake Shortt and Marta Chesi and Bergsagel, {Peter Leif} and Michael Bots and Johannes Zuber and Lowe, {Scott W.} and Johnstone, {Ricky W.} and Smyth, {Mark J.}",
year = "2012",
month = "10",
day = "11",
doi = "10.1182/blood-2012-04-426643",
language = "English (US)",
volume = "120",
pages = "3019--3029",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "15",

}

TY - JOUR

T1 - NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma

AU - Mattarollo, Stephen R.

AU - West, Alison C.

AU - Steegh, Kim

AU - Duret, Helene

AU - Paget, Christophe

AU - Martin, Ben

AU - Matthews, Geoffrey M.

AU - Shortt, Jake

AU - Chesi, Marta

AU - Bergsagel, Peter Leif

AU - Bots, Michael

AU - Zuber, Johannes

AU - Lowe, Scott W.

AU - Johnstone, Ricky W.

AU - Smyth, Mark J.

PY - 2012/10/11

Y1 - 2012/10/11

N2 - Immunomodulators are effective in controlling hematologic malignancy by initiating or reactivating host antitumor immunity to otherwise poorly immunogenic and immune suppressive cancers. We aimed to boost antitumor immunity in B-cell lymphoma by developing a tumor cell vaccine incorporating (α-galactosylceramide (α-GalCer) that targets the immune adjuvant properties of NKT cells. In the Eμ-myc transgenic mouse model, single therapeutic vaccination of irradiated, (α-GalCer-loaded autologous tumor cells was sufficient to significantly inhibit growth of established tumors and prolong survival. Vaccine-induced antilymphoma immunity required NKT cells, NK cells, and CD8 T cells, and early IL-12-dependent production of IFN-γ. CD4 T cells, gamma/delta T cells, and IL-18 were not critical. Vaccine treatment induced a large systemic spike of IFN-(γ and transient peripheral expansion of both NKT cells and NK cells, the major sources of IFN-γ. Furthermore, this vaccine approach was assessed in several other hematopoietic tumor models and was also therapeutically effective against AMLETO9a acute myeloid leukemia. Replacing (α-GalCer with β-mannosylceramide resulted in prolonged protection against Eμ-myc lymphoma. Overall, our results demonstrate a potent immune adjuvant effect of NKT cell ligands in therapeutic anticancer vaccination against oncogenedriven lymphomas, and this work supports clinical investigation of NKT cell-based immunotherapy in patients with hematologic malignancies.

AB - Immunomodulators are effective in controlling hematologic malignancy by initiating or reactivating host antitumor immunity to otherwise poorly immunogenic and immune suppressive cancers. We aimed to boost antitumor immunity in B-cell lymphoma by developing a tumor cell vaccine incorporating (α-galactosylceramide (α-GalCer) that targets the immune adjuvant properties of NKT cells. In the Eμ-myc transgenic mouse model, single therapeutic vaccination of irradiated, (α-GalCer-loaded autologous tumor cells was sufficient to significantly inhibit growth of established tumors and prolong survival. Vaccine-induced antilymphoma immunity required NKT cells, NK cells, and CD8 T cells, and early IL-12-dependent production of IFN-γ. CD4 T cells, gamma/delta T cells, and IL-18 were not critical. Vaccine treatment induced a large systemic spike of IFN-(γ and transient peripheral expansion of both NKT cells and NK cells, the major sources of IFN-γ. Furthermore, this vaccine approach was assessed in several other hematopoietic tumor models and was also therapeutically effective against AMLETO9a acute myeloid leukemia. Replacing (α-GalCer with β-mannosylceramide resulted in prolonged protection against Eμ-myc lymphoma. Overall, our results demonstrate a potent immune adjuvant effect of NKT cell ligands in therapeutic anticancer vaccination against oncogenedriven lymphomas, and this work supports clinical investigation of NKT cell-based immunotherapy in patients with hematologic malignancies.

UR - http://www.scopus.com/inward/record.url?scp=84867795406&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867795406&partnerID=8YFLogxK

U2 - 10.1182/blood-2012-04-426643

DO - 10.1182/blood-2012-04-426643

M3 - Article

C2 - 22932803

AN - SCOPUS:84867795406

VL - 120

SP - 3019

EP - 3029

JO - Blood

JF - Blood

SN - 0006-4971

IS - 15

ER -